DK3209686T3 - Monoklonale anti-gpc-1-antistoffer og anvendelser deraf - Google Patents
Monoklonale anti-gpc-1-antistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK3209686T3 DK3209686T3 DK14904438.0T DK14904438T DK3209686T3 DK 3209686 T3 DK3209686 T3 DK 3209686T3 DK 14904438 T DK14904438 T DK 14904438T DK 3209686 T3 DK3209686 T3 DK 3209686T3
- Authority
- DK
- Denmark
- Prior art keywords
- gpc
- antibodies
- applications
- monoclonal anti
- monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/AU2014/000999 WO2016061608A1 (en) | 2014-10-23 | 2014-10-23 | Monoclonal ανίί-gpc-l antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3209686T3 true DK3209686T3 (da) | 2020-03-16 |
Family
ID=55759935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14904438.0T DK3209686T3 (da) | 2014-10-23 | 2014-10-23 | Monoklonale anti-gpc-1-antistoffer og anvendelser deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10577418B2 (da) |
| EP (1) | EP3209686B1 (da) |
| JP (1) | JP6749901B2 (da) |
| KR (1) | KR102249981B1 (da) |
| CN (1) | CN107108734B (da) |
| AU (1) | AU2014409558B2 (da) |
| CA (1) | CA2964179C (da) |
| DK (1) | DK3209686T3 (da) |
| ES (1) | ES2778100T3 (da) |
| SG (1) | SG11201703006QA (da) |
| WO (1) | WO2016061608A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201708624YA (en) * | 2015-04-20 | 2017-11-29 | Minomic Int Ltd | Therapeutic antibodies and uses thereof |
| US20200308299A1 (en) * | 2017-04-28 | 2020-10-01 | National University Corporation Kochi University | Anti-gpc-1 antibody |
| AU2020212534A1 (en) * | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| JP2020007315A (ja) * | 2019-08-02 | 2020-01-16 | ミノミック インターナショナル リミティド | モノクローナル抗ｇｐｃ−１抗体およびその使用 |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU642419B2 (en) | 1989-05-24 | 1993-10-21 | South Eastern Sydney Area Health Service | Monoclonal antibodies which recognise malignant cells from bladder carcinomas |
| JPH05504466A (ja) * | 1989-05-24 | 1993-07-15 | ザ セントラル シドニー エリア ヘルス サービス | 膀胱癌からの悪性細胞を認識するモノクローナル抗体 |
| US5622836A (en) * | 1989-05-24 | 1997-04-22 | The University Of Sydney | Monoclonal antibodies which recognize malignant cells from bladder carcinomas |
| US5622835A (en) | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
| CN101070345B (zh) * | 2006-05-12 | 2010-09-29 | 中国科学院上海生命科学研究院 | 抗前列腺特异抗原psa单克隆抗体及应用 |
| KR102366820B1 (ko) | 2014-01-17 | 2022-02-22 | 미노믹 인터내셔널 리미티드 | 진단을 위한 세포 표면 전립선암 항원 |
| DK3245219T3 (da) | 2015-01-16 | 2020-06-29 | Glyp Holdings Pty Ltd | Glypicanepitoper og anvendelser deraf |
| SG11201708624YA (en) | 2015-04-20 | 2017-11-29 | Minomic Int Ltd | Therapeutic antibodies and uses thereof |
-
2014
- 2014-10-23 EP EP14904438.0A patent/EP3209686B1/en active Active
- 2014-10-23 KR KR1020177013513A patent/KR102249981B1/ko active IP Right Grant
- 2014-10-23 AU AU2014409558A patent/AU2014409558B2/en active Active
- 2014-10-23 ES ES14904438T patent/ES2778100T3/es active Active
- 2014-10-23 CA CA2964179A patent/CA2964179C/en active Active
- 2014-10-23 JP JP2017522028A patent/JP6749901B2/ja active Active
- 2014-10-23 US US15/520,722 patent/US10577418B2/en active Active
- 2014-10-23 DK DK14904438.0T patent/DK3209686T3/da active
- 2014-10-23 WO PCT/AU2014/000999 patent/WO2016061608A1/en active Application Filing
- 2014-10-23 CN CN201480083863.8A patent/CN107108734B/zh active Active
- 2014-10-23 SG SG11201703006QA patent/SG11201703006QA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016061608A8 (en) | 2017-06-29 |
| SG11201703006QA (en) | 2017-05-30 |
| EP3209686A4 (en) | 2018-03-07 |
| KR20170085051A (ko) | 2017-07-21 |
| KR102249981B1 (ko) | 2021-05-11 |
| AU2014409558B2 (en) | 2021-08-12 |
| AU2014409558A1 (en) | 2017-05-04 |
| CN107108734A (zh) | 2017-08-29 |
| JP2017531442A (ja) | 2017-10-26 |
| US20180072803A1 (en) | 2018-03-15 |
| ES2778100T3 (es) | 2020-08-07 |
| EP3209686B1 (en) | 2019-12-25 |
| JP6749901B2 (ja) | 2020-09-02 |
| EP3209686A1 (en) | 2017-08-30 |
| AU2014409558A8 (en) | 2019-08-08 |
| CN107108734B (zh) | 2021-09-14 |
| WO2016061608A1 (en) | 2016-04-28 |
| CA2964179A1 (en) | 2016-04-28 |
| CA2964179C (en) | 2023-04-11 |
| US10577418B2 (en) | 2020-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| DK3468990T3 (da) | Anti-C5-antistoffer og anvendelser deraf | |
| DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| DK3350220T3 (da) | Anti-pro/latente-myostatin-antistoffer og anvendelser deraf | |
| DK3274370T3 (da) | Anti-ceacam6-antistoffer og anvendelser deraf | |
| DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
| DK3353212T3 (da) | Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf | |
| DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
| DK3149042T3 (da) | PD-L1-antistoffer og anvendelser deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3191135T3 (da) | Anti-HER2-antistoffer og immunokonjugater | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3309174T3 (da) | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf | |
| DK3463435T3 (da) | Alpha-synuklein-antistoffer og anvendelser deraf | |
| DK3316909T3 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf |